0 CHECKOUT

Breast Cancer Drug Discoveries: What the Future Holds

  • ID: 679630
  • August 2011
  • 382 Pages
  • Espicom Business Intelligence Ltd

In 2010, almost 50% of breast cancer sales were due to three branded targeted therapies. With a large unmet clinical need, further agents are required to increase survival and delay disease progression.

Unique breast cancer market share, sales forecasts by launched and Phase III products to 2017

A comprehensive and critical examination and scoring of 72 major breast cancer treatments

Comprehensive market assessment of therapeutic approaches, company share, portfolios and prospects

Breast Cancer Therapy Sales Forecast 2010 - 2017

'What's the story behind this chart?'

The changing competitive landscape

By 2017, Espicom forecasts a modest increase in the number of players in the market-place compared to 2010, with Roche, and GlaxoSmithKline to a lesser extent, triumphing with targeted therapies directed against the specific subset of BC patients with HER2-positive disease. AstraZeneca, Novartis and Pfizer will face widespread generic competition for their hormonal therapies, leading to a loss of market share. Similarly, Sanofi and Eli Lilly will face declining sales for their chemotherapies.

The market in 2010...

In recent READ MORE >

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. Online access is provided for this product. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

  • Quick Help: The report will be emailed to you. Online access is provided for this product. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS

Our Clients

  • C.R. Bard, Inc.
  • GlaxoSmithKline PLC
  • Hologic Corporation
  • Provista Diagnostics, Inc.
  • Roche Diagnostics Ltd.
  • Genomic Health Inc.